Nanjing Vazyme Biotech Co Ltd banner
N

Nanjing Vazyme Biotech Co Ltd
SSE:688105

Watchlist Manager
Nanjing Vazyme Biotech Co Ltd
SSE:688105
Watchlist
Price: 19.2 CNY -2.69% Market Closed
Market Cap: ¥7.6B

Nanjing Vazyme Biotech Co Ltd
Short-Term Debt

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
|
See Also

Nanjing Vazyme Biotech Co Ltd
Short-Term Debt Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Short-Term Debt CAGR 3Y CAGR 5Y CAGR 10Y
N
Nanjing Vazyme Biotech Co Ltd
SSE:688105
Short-Term Debt
¥554.3m
CAGR 3-Years
N/A
CAGR 5-Years
73%
CAGR 10-Years
N/A
Beigene Ltd
HKEX:6160
Short-Term Debt
¥0
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Innovent Biologics Inc
HKEX:1801
Short-Term Debt
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
RemeGen Co Ltd
SSE:688331
Short-Term Debt
¥1.2B
CAGR 3-Years
116%
CAGR 5-Years
63%
CAGR 10-Years
N/A
Akeso Inc
HKEX:9926
Short-Term Debt
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
S
Sichuan Kelun-Biotech Biopharmaceutical Co Ltd
HKEX:6990
Short-Term Debt
¥0
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Nanjing Vazyme Biotech Co Ltd
Glance View

Market Cap
7.6B CNY
Industry
Biotechnology

Nanjing Vazyme Biotech Co., Ltd. is an intriguing player in the biotechnology sector, having carved a niche in the research, development, and production of an array of innovative biological reagents and solutions. Established in the vibrant city of Nanjing, this company stands at the crossroads of science and commerce, offering products that span across PCR reagents, protein engineering, and enzyme solutions. Their expertise is rooted in leveraging cutting-edge molecular biology, allowing the company to cater to a diverse clientele that includes academic research institutions, healthcare providers, and industries that require precise biochemical testing and analysis. Vazyme's growth story is intertwined with the fields of molecular diagnostics and life sciences, industries that have seen rapid advancements and heightened demand, especially in recent years. The company generates revenue predominantly through the sale of high-quality reagents that are essential for the accurate and reliable processing of biological data. By continually incorporating the latest scientific breakthroughs into their products, they ensure that their solutions remain at the forefront of the market. This strategy not only enhances their competitive edge but also solidifies customer loyalty and expands their market presence across the globe, establishing Vazyme as a key contributor to the biotechnology landscape.

Intrinsic Value
11.13 CNY
Overvaluation 42%
Intrinsic Value
Price ¥19.2
N

See Also

What is Nanjing Vazyme Biotech Co Ltd's Short-Term Debt?
Short-Term Debt
554.3m CNY

Based on the financial report for Dec 31, 2024, Nanjing Vazyme Biotech Co Ltd's Short-Term Debt amounts to 554.3m CNY.

What is Nanjing Vazyme Biotech Co Ltd's Short-Term Debt growth rate?
Short-Term Debt CAGR 5Y
73%

Over the last year, the Short-Term Debt growth was -51%.

Back to Top
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett